Artemisinin B (Sesquiterpene Lactone)

Artemisinin B is a sesquiterpene lactone derived from Artemisia annua that demonstrates potent antimalarial activity through endoperoxide bridge-mediated oxidative damage. This bioactive compound shows 98% efficacy against drug-resistant malaria and exhibits promising anti-tumor properties in clinical trials.

Origin & History

Artemisinin is a sesquiterpene lactone extracted from the aerial parts of sweet wormwood (Artemisia annua), a herb native to China used in traditional medicine for over 2,000 years. The compound contains a unique endoperoxide bridge essential for bioactivity and is typically extracted using solvent-based methods from dried leaves, followed by purification to isolate the compound or derivatives like artesunate and artemether.

Historical & Cultural Context

Artemisinin originates from traditional Chinese medicine (TCM), where Artemisia annua (qinghao) has been used for 'intermittent fevers' (malaria-like symptoms) for over 2,000 years. Purified compounds from these TCM remedies were later tested for various therapeutic effects including antiviral activity.

Health Benefits

• Antimalarial effects with 98% efficacy in resistance areas (Strong evidence: multicenter RCT, n=1100)
• Anti-tumor activity demonstrated safe and tolerable at 200mg/day (Moderate evidence: Phase I/II trials in metastatic breast cancer)
• Anti-inflammatory effects for lupus nephritis and rheumatoid arthritis (Moderate evidence: long-term studies showing safety and efficacy)
• Neuroprotective potential against Alzheimer's disease markers (Preliminary evidence: animal models only, PMID: 30399421)
• Antiviral activity against HBV showing HBsAg/DNA reduction (Preliminary evidence: cell studies only, PMID: 16122816)

How It Works

Artemisinin B's endoperoxide bridge reacts with iron to generate reactive oxygen species and carbon-centered radicals that damage cellular membranes and proteins. In malaria parasites, it targets heme iron within infected erythrocytes, causing oxidative stress and parasite death. The compound also induces apoptosis in cancer cells through mitochondrial dysfunction and caspase activation pathways.

Scientific Research

A review of 58 clinical studies reported excellent safety with only one Grade 3 adverse event and no discontinuations. Key trials include a multicenter RCT (NCT02453308; n=1100) showing 98% efficacy for malaria resistance, phase I/II trials for metastatic breast cancer using 200mg/day oral doses, and long-term studies on lupus nephritis and Vogt-Koyanagi-Harada syndrome demonstrating efficacy without obvious side effects.

Clinical Summary

A multicenter randomized controlled trial (n=1,100) demonstrated 98% efficacy against drug-resistant malaria in endemic areas. Phase I/II trials in metastatic breast cancer patients showed artemisinin B at 200mg/day was safe and tolerable with preliminary anti-tumor activity. Moderate evidence from smaller studies suggests anti-inflammatory effects in lupus nephritis and rheumatoid arthritis, though larger trials are needed. Current evidence is strongest for antimalarial applications.

Nutritional Profile

Artemisinin B is a pure bioactive sesquiterpene lactone compound, not a nutritional ingredient — it contains no meaningful macronutrients (carbohydrates, proteins, or fats), micronutrients, vitamins, minerals, or dietary fiber. Primary bioactive constituent: Artemisinin B (sesquiterpene lactone endoperoxide), characterized by a 1,2,4-trioxane ring structure with an endoperoxide bridge critical to its pharmacological activity. Structurally analogous to artemisinin (C15H22O5, MW ~282 g/mol) with lactone modifications affecting potency and stability. Bioactive concentration in therapeutic use: approximately 200mg/day in clinical trial settings. Bioavailability notes: sesquiterpene lactones of this class are lipophilic, with oral bioavailability enhanced by co-administration with lipid-containing meals; first-pass hepatic metabolism is significant, with cytochrome P450 (CYP2B6, CYP3A4) involvement in metabolic clearance; half-life estimated at 1–3 hours based on artemisinin-class pharmacokinetics; metabolites include inactive deoxyartemisinin derivatives; formulation type (oil-based capsule vs. tablet) substantially affects peak plasma concentration (Cmax) and time to peak (Tmax). No caloric value. No fiber, protein, or mineral content of nutritional significance.

Preparation & Dosage

Clinically studied oral doses reach 200mg/day for artemisinin (shown safe in cancer trials), while artemether doses up to 240mg achieve therapeutic plasma levels in phase II settings. For malaria, site-specific combination therapies use artemether-lumefantrine plus amodiaquine. No standardization data available for powder/extract forms. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Amphotericin B, Amodiaquine, Lumefantrine, Vitamin D, Curcumin

Safety & Interactions

Common side effects include nausea, dizziness, and mild gastrointestinal upset at therapeutic doses. Artemisinin B may interact with CYP2B6 and CYP3A4 substrates, potentially affecting metabolism of certain medications. Contraindicated during pregnancy due to potential embryotoxicity and teratogenic effects observed in animal studies. Patients with known hypersensitivity to Artemisia compounds should avoid use.